Stoke Therapeutics (NASDAQ:STOK) Stock Price Down 5.4% - What's Next?

Key Points

• Stoke Therapeutics shares fell 5.4% to $20.80, with trading volume dropping 90% below the average, signaling potential concerns among investors.
• Analysts maintain an overall positive outlook with a consensus target price of $25.57, as multiple firms, including Cantor Fitzgerald and Jefferies Financial Group, issued "buy" ratings.
• Despite the stock decline, the company reported better-than-expected earnings per share of ($0.40), exceeding consensus estimates of ($0.57).

Stoke Therapeutics, Inc. (NASDAQ:STOK - Get Free Report) dropped 5.4% during mid-day trading on Tuesday . The stock traded as low as $21.03 and last traded at $20.80. 82,366 shares were traded during trading, a decline of 90% from the average daily volume of 807,927 shares. The stock had previously closed at $21.99.

Wall Street Analyst Weigh In

Several research analysts have recently weighed in on STOK shares. BTIG Research set a $28.00 price target on shares of Stoke Therapeutics and gave the stock a "buy" rating in a research note on Monday, August 18th. Jefferies Financial Group began coverage on Stoke Therapeutics in a report on Friday, July 18th. They set a "buy" rating and a $30.00 price target for the company. Needham & Company LLC reaffirmed a "buy" rating and set a $22.00 price objective on shares of Stoke Therapeutics in a research report on Tuesday, July 1st. Wedbush increased their target price on shares of Stoke Therapeutics from $16.00 to $22.00 and gave the stock an "outperform" rating in a report on Wednesday, August 13th. Finally, Chardan Capital reiterated a "buy" rating and issued a $24.00 price target on shares of Stoke Therapeutics in a research report on Wednesday, August 13th. Two research analysts have rated the stock with a Strong Buy rating and seven have assigned a Buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of "Buy" and an average target price of $25.57.

Stoke Therapeutics Stock Performance

The company has a market capitalization of $1.29 billion, a P/E ratio of 27.60 and a beta of 1.14. The business's fifty day simple moving average is $16.05 and its 200-day simple moving average is $11.54.

Stoke Therapeutics (NASDAQ:STOK - Get Free Report) last announced its quarterly earnings results on Tuesday, August 12th. The company reported ($0.40) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.57) by $0.17. The company had revenue of $13.82 million for the quarter, compared to the consensus estimate of $31.51 million. Stoke Therapeutics had a net margin of 26.25% and a return on equity of 18.32%. As a group, analysts forecast that Stoke Therapeutics, Inc. will post -2.01 EPS for the current year.

Insider Buying and Selling at Stoke Therapeutics

In other Stoke Therapeutics news, General Counsel Jonathan Allan sold 6,345 shares of Stoke Therapeutics stock in a transaction on Wednesday, September 3rd. The shares were sold at an average price of $20.07, for a total value of $127,344.15. Following the sale, the general counsel directly owned 11,831 shares in the company, valued at approximately $237,448.17. The trade was a 34.91% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, insider Barry Ticho sold 5,501 shares of Stoke Therapeutics stock in a transaction on Tuesday, September 2nd. The stock was sold at an average price of $19.87, for a total transaction of $109,304.87. Following the completion of the transaction, the insider directly owned 18,469 shares of the company's stock, valued at $366,979.03. The trade was a 22.95% decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have sold 107,719 shares of company stock worth $2,063,359. Insiders own 9.50% of the company's stock.

Hedge Funds Weigh In On Stoke Therapeutics

Institutional investors and hedge funds have recently made changes to their positions in the business. BNP Paribas Financial Markets grew its stake in shares of Stoke Therapeutics by 66.2% in the 2nd quarter. BNP Paribas Financial Markets now owns 4,186 shares of the company's stock worth $48,000 after buying an additional 1,668 shares in the last quarter. Tower Research Capital LLC TRC boosted its stake in shares of Stoke Therapeutics by 461.0% during the 2nd quarter. Tower Research Capital LLC TRC now owns 4,370 shares of the company's stock worth $50,000 after purchasing an additional 3,591 shares during the period. GAMMA Investing LLC boosted its stake in shares of Stoke Therapeutics by 1,842.0% during the 1st quarter. GAMMA Investing LLC now owns 5,360 shares of the company's stock worth $36,000 after purchasing an additional 5,084 shares during the period. Osaic Holdings Inc. boosted its stake in shares of Stoke Therapeutics by 263.3% during the 2nd quarter. Osaic Holdings Inc. now owns 7,488 shares of the company's stock worth $85,000 after purchasing an additional 5,427 shares during the period. Finally, Police & Firemen s Retirement System of New Jersey boosted its stake in shares of Stoke Therapeutics by 33.2% during the 2nd quarter. Police & Firemen s Retirement System of New Jersey now owns 9,558 shares of the company's stock worth $108,000 after purchasing an additional 2,384 shares during the period.

About Stoke Therapeutics

Stoke Therapeutics, Inc, an early-stage biopharmaceutical company, develops medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary targeted augmentation of nuclear gene output to develop antisense oligonucleotides to selectively restore protein levels.